Picture of Effector Therapeutics logo

EFTR — Effector Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

eFFECTOR Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

* eFFECTOR Therapeutics Inc  EFTR.OQ  reported a quarterly
adjusted loss of 24 cents​​ per share for the quarter ended in
March. The mean expectation of four analysts for the quarter was
for a loss of 14 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * eFFECTOR Therapeutics Inc's reported EPS for the quarter
was a
loss of 24 cents​.
    * The mean earnings estimate of analysts had risen by
about 38.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * eFFECTOR Therapeutics Inc shares had risen by 53.1% this
quarter and gained 26.3% so far this year.
    * The company reported a quarterly loss of $10 million.
    * Wall Street's median 12-month price target for eFFECTOR
Therapeutics Inc is $7.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 10:22 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.14          -0.24          Missed
 Dec. 31 2022      -0.24          -0.22          Beat
 Sep. 30 2022      -0.21          -0.23          Missed
 Jun. 30 2022      -0.16          -0.17          Missed

Recent news on Effector Therapeutics

See all news